GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Korro Bio Inc (NAS:KRRO) » Definitions » Price-to-Owner-Earnings

Korro Bio (Korro Bio) Price-to-Owner-Earnings : (As of Jun. 06, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Korro Bio Price-to-Owner-Earnings?

As of today (2024-06-06), Korro Bio's share price is $47.25. Korro Bio does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Korro Bio's Price-to-Owner-Earnings or its related term are showing as below:


KRRO's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.81
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-06), Korro Bio's share price is $47.25. Korro Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-53.08. Therefore, Korro Bio's PE Ratio for today is At Loss.

As of today (2024-06-06), Korro Bio's share price is $47.25. Korro Bio's EPS without NRI for the trailing twelve months (TTM) ended in was $-53.08. Therefore, Korro Bio's PE Ratio without NRI for today is At Loss.


Korro Bio Price-to-Owner-Earnings Historical Data

The historical data trend for Korro Bio's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Korro Bio Price-to-Owner-Earnings Chart

Korro Bio Annual Data
Trend Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - -

Korro Bio Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings - - - - -

Competitive Comparison of Korro Bio's Price-to-Owner-Earnings

For the Biotechnology subindustry, Korro Bio's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Korro Bio's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Korro Bio's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Korro Bio's Price-to-Owner-Earnings falls into.



Korro Bio Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Korro Bio's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=47.25/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Korro Bio  (NAS:KRRO) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Korro Bio Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Korro Bio's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Korro Bio (Korro Bio) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
One Kendall Square, Suite 6-401, Building 600-700, Cambridge, MA, USA, 02139
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Executives
David L. Lucchino director, officer: President and CEO C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Rick Yang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Edward T Mathers 10 percent owner C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Nessan Bermingham director 890 WINTER STREET, WALTHAM MA 02451
Atlas Venture Associates Xi, Llc 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
New Enterprise Associates 17, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 17, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea 17 Gp, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund Ii, L.p. 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Llc 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Lp 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Steve Colletti officer: Chief Scientific Officer C/O KORRO BIO, INC., ONE KENDALL SQUARE, BUILDING 600-700, CAMBRIDGE MA 02139
Shelby J. Walker officer: See Remarks C/O KORRO BIO, INC., ONE KENDALL SQUARE, BUILDING 600-700, CAMBRIDGE MA 02139

Korro Bio (Korro Bio) Headlines

From GuruFocus

Korro Announces $70 Million Private Placement

By Marketwired 04-18-2024